Jazz Pharmaceuticals Inc. is raising about $58.5 million in a public offering to pay off a sizeable chunk of its outstanding debt ahead of an FDA decision on fibromyalgia drug JZP-6 (sodium oxybate), expected this fall. (BioWorld Today)
CHICAGO - Before the so-called genomics bubble burst, it seemed any company with the word "genomics" in its name was a sure winner with investors, and the "average" biotech was able to stay afloat in both public and private markets. (BioWorld Today - 2010 BIO)
CHICAGO - Biotech's approach to business development has long had the familiar get-through-Phase-II-proof-of-concept-and-then-partner ring to it. And it's a strategy that certainly has served the industry well, with biotechs scoring impressive deal terms and gaining experienced partners to run (and often fund) large pivotal trials and commercialization efforts. (BioWorld Today - 2010 BIO)
CHICAGO - Day two of 2010 Biotechnology Industry Organization convention kicked into high gear, and amid the early morning offerings was a panel session on gene patenting that its host dubbed "incredibly timely." (BioWorld Today - 2010 BIO)
